Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Osteonecrosis of the jaw (ONJ) is a rare but severe disease which has been diagnosed in women with breast cancer on a bisphosphonate (BP) therapy. Thus, the German society of senology appointed a multidisciplinary task force to establish a consensus on the use of bisphosphonates in breast cancer patients with bone metastases, considering in particular the possible risk of ONJ. This report summarizes the results and recommendations for the prevention and treatment of ONJ in breast cancer patients receiving BP.
Fehm
T
T
University Women's Hospital Tübingen, Calwer Strasse 7, 72076 Tübingen, Germany. tanja.fehm@med.uni-tuebingen.de
Felsenberg
D
D
Krimmel
M
M
Solomayer
E
E
Wallwiener
D
D
Hadjii
P
P
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology*; D015897:Comorbidity; D003729:Dental Care; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors
D004164:Diphosphonates